 |
|
|
| |
Continued suppression of viral markers observed following discontinuation of nucleos(t)ide analogue therapy in chronic hepatitis B subjects with low hepatitis B surface antigen levels after 48 weeks of treatment with AB-729
|
| |
| |
EASL 2022 June 22-26 London
M-F Yuen1, SI Strasser2, W Sukeepaisarnjaroen3, J Holmes4, V Sharma5, D Antoniello5, E Medvedeva5, EP Thi6, G Picchio5, T Eley5, KD Sims5
1Queen Mary Hospital, The University of Hong Kong, Hong Kong, 2Royal Prince Alfred Hospital, Sydney, Australia, 3Srinagarind Hospital, Khon Kaen University, Khon Kaen, Thailand,
4St. Vincent's Hospital, Melbourne, Australia, 5Arbutus Biopharma Clinical Development, 6Arbutus Biopharma Research
|
| |
|
|
|
|
|
